Literature DB >> 1379260

Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum.

W H Daughaday1, B Trivedi.   

Abstract

We have reported that normal human sera contain immunoactivity (IA) detected by a RIA directed against the first 21 amino acids of the E domain of proinsulin-like growth factor-II (pro-IGF-II). Marked elevations of E-21 IA were found in the serum of patients with nonislet cell hypoglycemia (NICTH) and patients with renal failure receiving chronic hemodialysis. In this paper we describe some of the properties of the E-21 IA of normal and abnormal sera. The E-21 IA eluted from a calibrated acid Sephadex G-50 column as two major peaks. In normal serum the first major peak had a mol wt (Mr) between 14,000-15,000, and the second peak had a Mr between 5,000-6,000. When E-21 IA from serum of a patient with NICTH was similarly studied, most of the IA was present as a Mr 11,000 peak and only a small amount was present as a 5,000-6,000 Mr peak. In contrast, most of the E-21 IA present in the sera of patients on hemodialysis was present in the smaller molecular form, which eluted from a reverse phase column as a single component. This small Mr peak lacked determinants for the IGF-II monoclonal antibody (Amano), for pooled serum IGF-binding proteins, and for the IGF-I receptors on human placental membranes. We suggest that the 15- and 11-kilodalton peaks represent the glycated and unglycated forms of pro-IGF-II (E-21) reported by others. The glycated form appears to predominate in normal serum, whereas the nonglycated form predominates in the serum of patients with NICTH and renal failure. The 5,000-6,000 Mr E-21 IA probably represents a fragment of the free E domain of pro-IGF-II. Its size is consistent with cleavage of the free E domain between Arg46 and Arg47. The accumulation of this E-21 IA in renal failure is evidence that the kidney has a major role in the clearance of this fragment, which is not accomplished by the membranes used in hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379260     DOI: 10.1210/jcem.75.2.1379260

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion.

Authors:  C M Buchanan; A R Phillips; G J Cooper
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

2.  Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.

Authors:  W H Daughaday; B Trivedi; R C Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

3.  Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.

Authors:  S Kalla Singh; D Moretta; F Almaguel; N R Wall; M De León; D De León
Journal:  Growth Factors       Date:  2007-12       Impact factor: 2.511

4.  Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature.

Authors:  Pinaki Dutta; Anuradha Aggarwal; Yashpal Gogate; Uma Nahar; Viral N Shah; Mandeep Singla; N Khandelwal; Anil Bhansali
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-11-20

Review 5.  Doege-Potter syndrome: A review of the literature including a new case report.

Authors:  Guiyan Han; Zhimin Zhang; Xingbin Shen; Kunpeng Wang; Yang Zhao; Jianqiu He; Yu Gao; Xiujie Shan; Guohua Xin; Chunhui Li; Xiaoyan Liu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.